Australian and International Cannabis Industry: Market Developments and Investment Risks
The cannabis industry has developed differently across countries, with changes in medicinal access, adult-use legislation, product regulation and commercial investment creating opportunities and risks. Historical reports from 2019 illustrate how regulatory decisions, consumer demand, supply conditions and investor expectations influenced the sector at that time.
Medicinal cannabis access in Australia
Australian media reports from 2019 described increasing demand for medicinal cannabis and growing public discussion about patient access. One report cited 2,919 medicinal cannabis prescriptions approved by the Therapeutic Goods Administration (TGA) in a month, stating that this was more than two and a half times the number processed six months earlier.
These figures are historical and should not be treated as current prescribing statistics. They also require careful interpretation: prescription approvals do not, by themselves, establish the number of patients treated, clinical effectiveness or the commercial value of the market.
Public debate during this period included patient access, the cost of treatment and the regulatory distinction between medicinal cannabis and adult-use cannabis.
International regulatory developments
Developments in other countries demonstrated how different regulatory frameworks shaped cannabis markets.
Canada: In October 2019, regulations permitting the production and sale of additional cannabis products, including edibles and extracts, came into effect. Reports from the period also noted that unregulated sales remained a challenge after the introduction of the legal adult-use market.
United States: State-level legalisation created different markets and licensing systems. Reports described investment in cultivation facilities, secondary-market transactions involving business licences and proposals to use cannabis tax revenue to support public programmes.
France: In 2019, lawmakers considered funding a medicinal cannabis trial involving approximately 3,000 patients. The proposal illustrated the potential role of clinical trials in assessing new treatment pathways and establishing regulated supply arrangements.
These examples describe historical developments, not current legal or commercial conditions. Each country's present requirements must be assessed separately.
Commercial opportunities and operational risks
The 2019 reports highlighted several factors affecting cannabis businesses:
Cultivation and processing: Demand expectations encouraged investment in production facilities, while weather events and crop losses demonstrated the risks associated with agricultural operations.
Licensing: Cannabis business licences could be costly and time-consuming to obtain. Secondary-market purchases were reported as an alternative in some jurisdictions, but they carried legal, financial and due-diligence considerations.
Product development: Changes to regulations created opportunities for businesses involved in extracts, edibles and other product categories.
Hemp and CBD: Increased interest in hemp-derived CBD encouraged cultivation and processing investment. Reported acreage and revenue estimates were market-specific projections and should not be treated as guaranteed returns.
Advertising and technology: Cannabis technology and advertising businesses were exposed to regulatory restrictions, changes in market rollout and fluctuations in investor funding.
Investment volatility
Cannabis equities experienced substantial volatility during the industry's early period of public-market expansion. Reports from 2019 described significant share-price declines among Canadian cannabis companies after earlier market enthusiasm.
These developments demonstrate why investment decisions should not rely solely on market-growth forecasts or expectations of legalisation. Investors should assess:
Financial statements, cash flow and debt.
Production costs and capacity utilisation.
Licensing and regulatory compliance.
Access to distribution and established customers.
Competition from legal and unregulated markets.
Capital requirements and the risk of further fundraising.
Management experience and the reliability of company disclosures.
Medicinal use and clinical evidence
Historical reports identified chronic pain as a common reason for medicinal cannabis use among patients in the United States. A study reported in 2019 found that approximately 65 per cent of the patients examined used cannabis for chronic pain.
That finding describes reported patient use; it does not establish that cannabis is effective for every person with chronic pain. Clinical evidence varies by condition, cannabinoid, formulation and dosage. Treatment decisions should be made with qualified healthcare professionals.
Conclusion
The historical developments reported in 2019 show that cannabis markets are influenced by regulation, patient access, product innovation, agricultural conditions, competition and investor sentiment. They also demonstrate that market expansion does not guarantee business profitability or stable share prices.
Anyone assessing the Australian medicinal cannabis sector should use current regulatory information and independently verified financial and operational data rather than relying on historical headlines or promotional market projections.
Historical source reports